Q3 2025 Earnings Call Transcript October 29, 2025 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is ...
Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia ...
6don MSN
Vanda narrows 2025 revenue guidance to $210M-$230M amid Fanapt growth and strategic investments
Q3 2025 Management View CEO Mihael Polymeropoulos reported "strong commercial execution with total net product sales reaching ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback